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Abstract The X-linked genetic Fabry disease causes
multiorgan lesions due to intracellular storage of the sub-
strate globotriaosylceramide. Neurological involvement
ranges from painful, small fiber neuropathy to cerebro-
vascular disorders to multifocal aggressive forms. Disease
identification through proper differential diagnosis and
timely assessment of organ damage should guide a careful
treatment planning. Mainstay treatment, include enzyme
replacement and support therapy. Neurologists have a
pivotal role in early instrumental and clinical detection of
organ damage. A panel of experts has developed a set of
consensus recommendations to guide the approach of
neurologists to Fabry disease.
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Definition
Fabry disease is an X-linked lysosomal storage disorder
caused by the deficiency of the enzyme a-galactosidase A
(a-Gal A). Intracellular accumulation of the substrate
globotriaosylceramide (Gb3) leads to multiorgan lesions
[1, 2]. Fabry disease affects men, but it is often found in
heterozygous women as well.
Clinical pictures and course
The classic form of Fabry disease is generally observed in
male patients in the pediatric age group. Symptoms are
sometimes not recognized until the youth or adult age,
when organ lesions are already established. The earliest
manifestations of disease, painful neuropathy and angio-
keratoma, are observed in the majority of patients [3–6]:
72, and 88%, respectively, in our experience [7]. The onset
of painful neuropathy is observed on average around the
eleventh year of life, but it has also been reported in earlier
years. Gastrointestinal disturbances in young patients are
not rare. Cornea verticillata without alterations of vision is
a very frequent finding. Later, in adult men between 30 and
40 years, complications arise involving vital organs, i.e.,
the heart, central nervous system, and kidney (altered renal
function ranges from proteinuria to progressive renal fail-
ure leading to kidney transplant). Neurosensorial hearing
loss and paroxysmal vertigo can also be observed; the latter
may be an indication of labyrinth damage. Life expectancy
was about 41–50 years before enzyme replacement therapy
(ERT) and kidney transplant were available [3, 4, 6]. In
women, the clinical course is less aggressive, with onset
later in adult life. In women, and more rarely in men with
atypical clinical pictures, manifestations involving only
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one organ are paramount (e.g., central nervous system or
the heart, while angiokeratoma has only limited extension
or it is not referred to the physician by the patient, and
proteinuria is mild or absent), and painful neuropathy
seems to have a lower incidence than in men. The average
onset of painful neuropathy in women is around age
17 years, but it may also be observed in earlier years of
life. The Fabry registry reports a median age of onset at
10 years. Life expectancy in these patients is 55–70 years,
lower than the average life expectancy in women in the
general population [3, 4, 6].
From clinical hypothesis to diagnosis of Fabry disease:
opportunities for the neurologist
Early diagnosis is important to establish specific (i.e., ERT)
and symptomatic and preventive therapy. Clinical suspi-
cion of Fabry disease, if clinical pictures as those described
should occur, can be validated by clinical history, physical
examination with special attention to specific signs, and by
symptoms not spontaneously reported by the patient, such
as angiokeratoma and heat intolerance. Proteinuria, ECG
alterations (shortage of the PR interval), cornea verticillata,
and echocardiographic alterations suggestive of hypertro-
phic myocardiopathy are important clues for the disease.
However, such signs and symptoms may be absent or not
clearly defined in typical manifestations of the disease and
they are easily missed unless carefully sought for. When
suspecting Fabry disease, diagnosis is achieved as follows:
in men through a leukocyte a-galactosidase A assay (in
typical forms, activity is low or absent) later confirmed by
molecular genetic analysis; in women, DNA analysis is
strongly required. In women, leukocyte enzyme activity
shows strong inter-individual variability, ranging from
normal to significantly reduced values, probably because of
random inactivation of one of the X chromosomes in the
early stages of development. Central and peripheral ner-
vous system symptoms may also have diagnostic value,
and it is worth alerting the general practitioner and the
pediatrician of the changing clinical features of nervous
system involvement in Fabry disease [7–11]:
1. painful neuropathy (small fiber neuropathy);
2. cerebrovascular disorders (small and large vessel
disease and/or cardiovascular involvement with cere-
bral embolism);
3. aggressive clinical forms with central multifocal,
relapsing, and progressively invalidating symptoms,
with possibly superimposed inflammatory conditions
(aseptic meningitis, multiple sclerosis-like syndromes).
Involvement of peripheral nerves, with neuropathic pain
and acroparesthesia, which is triggered or worsened by
temperature increase, is the most frequent and early man-
ifestation of Fabry disease, and often the first one. These
symptoms are due to a dysfunctional condition of small
caliber nervous fibers [12–14].
Symptoms described above are observed in about 80% of
male patients, more rarely in women, and appear early. In
adults, symptoms may also be induced by stress and alcohol
intake. Upper and lower limbs are involved, particularly the
palm of the hands and the foot sole, while the skin color is not
affected and such symptoms are always associated with
paresthesia, mainly thermal sensitivity, while deep tendon
reflexes are preserved. Severity is variable among patients;
and variable in the same patient over time. Nerve conduction
studies (NCS) can be normal even in the late stages of the
disease, because small fiber involvement is the predominant
feature of the disease. The incidence of the carpal tunnel
syndrome looks higher than in the general population [13].
Owing to NCS results, small fiber neuropathy may be diffi-
cult to substantiate. Skin biopsy, revealing loss of axons and
osmophilic inclusions, may be useful in selected cases [15,
16]. Involvement of the autonomous nervous system is fre-
quent, and should carefully be looked (Table 1). Gastroin-
testinal manifestations of autonomous nervous system
involvement may range from abdominal pain to diarrhea and
rarely stypsis; in women abdominal pain may be considered,
by mistake, of gynecological origin. Altered sweating
function is a frequent and classic feature. High temperature
increases poor tolerance: fever, and high environmental
temperature, as well as physical exercise can trigger acute
pain at the extremities with weakness, which are often
intense, and generalized malaise (thermoregulation through
sweating is not effective in Fabry disease). Impaired auto-
nomic function with altered thermoregulatory sweating
causes such symptoms; such symptoms can also be seen with
low environmental temperature. Either hypotension (more
often) or hypertension may also be seen.
Table 1 Other conditions leading to painful neuropathy besides
Fabry disease
Differential diagnosis of painful neuropathy in Fabry disease
1. Juvenile rheumatoid arthritis
2. Pain from other rheumatic disorders
3. Pain commonly attributed to growth
4. Painful neuropathy in other inherited metabolic conditions
(e.g., amyloidosis and porphyria)
5. Painful neuropathy in other metabolic conditions (e.g., diabetes
mellitus type I, alcohol abuse, deficiency of vitamins)
6. Neuropathies in systemic vasculitides
7. Psychogenic pain
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Cochleovestibular disorders are also common, espe-
cially hypoacusia [17]. Cerebrovascular ischemic events
(brain infarctions or TIA) are present in over 25% of
patients, and their frequency increases with age. Involved
areas are mostly, although not exclusively, those supplied
by the posterior arterial circulation. An etiology of each
single event is hard to identify, and it is likely to be
mixed even in the same patient at different times:
arteriolar obstruction, arteriosclerosis, arterio-arterial
embolism and cardiogenic embolism are all potential
mechanisms. Magnetic resonance imaging (MRI) is use-
ful to assess nervous system lesions. Typically, MRI may
show lesions attributable to small infarctions and diffuse
alteration of the white matter, especially in deeper sec-
tions, with images suggestive of arteriolar involvement of
the perforating arteries (lacunar infarctions and leuko-
araiosis). These lesions are often silent, and they are
discovered at early stages in adult patients undergoing
screening and follow-up. In some instances, abnormalities
of brain MRI related to small vessel pathology (white
matter lesions) are the only signs leading to diagnosis of
Fabry disease [18, 19]. Characteristic, but non specific,
neuroradiological features of Fabry disease have been
found almost exclusively in men. Indeed, bilateral T1
hyperintensity can be seen in the posterior region of
thalamus (‘‘pulvinar sign’’) in male patients [20]. Except
for the ‘‘pulvinar sign’’ differential neuroradiological
diagnosis of Fabry’s CNS lesions with other vascular
pathologies or inflammatory disorders can be rather dif-
ficult. Vertebro-basilar arterial dolichoectasy is very
common in neuroimaging studies (38% in men, 57% in
women according to Rolfs et al., up to 87% in the report
of Fellgiebel et al.) [21, 22], even relatively early in the
course of the disease with the endothelial thickness still
normal. Transcranial Doppler data provides not conclu-
sive results in Fabry patients, and it still has no role in
the clinical management of individual cases [23, 24].
Fabry disease should always be considered in the dif-
ferential diagnosis of stroke in young age, even without
clinical evidence of cardiac or renal involvement. A
recent prospective study suggests that 4% of cryptoge-
netic strokes in the youth are attributable to Fabry dis-
ease, and 1–2% of patients with stroke between 18 and
55 years have Fabry disease [21]. Table 2 shows a list of
clinical conditions for the differential diagnosis with Fa-
bry disease. Etiology of stroke may be cardiac (cardio-
myopathy, valvulopathy, arrythmias), hypotensive or it
may follow deposition of GL3 in vessel walls. Embolic
strokes have been described in elderly women with Fabry
disease with cardiomyopathy and atrial fibrillation [25].
Glial scars following cortical necrosis in patients with
vascular encephalopathy may be epileptogenic and cause
seizures, albeit rarely. Cerebrospinal examination (CSF),
sometimes suggesting an altered blood–brain barrier
(BBB), is helpful in discriminating among different
putative causes.
Albeit rarely, acute and recurrent cerebrovascular events
may associate with aseptic meningitis, and CSF concen-
tration of proteins are increased due to an altered brain–
blood barrier [10]. In one case, a beneficial effect of high-
dose steroids has been reported [10].
Early evaluation of Fabry disease-related organ
damage and clinical course
Instrumental diagnosis allows for early detection of organ
damage before symptoms are established. Early detection
of organ damage is important because any treatment will
have more chances of success if started before irreversible
structural organ damage develops [7, 26]. Structural, irre-
versible organ damage can develop early in the asymp-
tomatic stage, but it is more extensive and diffuse in the
symptomatic stages of the disease. Direct correlation of
organ damage with Fabry disease should be documented by
biopsy whenever applicable. Of course, even when there is
no such direct evidence, clinical and instrumental investi-
gations will lead the expert physician to establish the cor-
relation between organ damage and Fabry disease.
Pathogenesis of organ damage is multifactorial in Fabry
disease as in many other monogenic diseases, and that
would explain the heterogeneity of phenotypic manifesta-
tions within the same family and in individuals of the same
sex and age [27]. Multifactorial pathogenesis is of special
value to explain how vasculopathy, with involvement of
small and large vessels, originates in Fabry disease. Early
documentation of organ damage, in addition to diagnosis,
is important in clinical practice to address treatment
options. Neurological signs and symptoms, even though
they are limited to peripheral neuropathy, frequently
Table 2 Other conditions, leading to stroke and vascular encepha-
lopathy, which should be differentiated from Fabry disease
Stroke and vascular encephalopathy in Fabry disease: differential
diagnosis
1. Juvenile cryptogenetic ischemic stroke
2. Juvenile ischemic stroke associated with other acquired risk
factors
3. Juvenile stroke in monogenic diseases (e.g., CADASIL,
homocystinuria)
4. Mitochondrial diseases (e.g., MELAS)
5. Central nervous system and systemic vasculitis
6. Multifocal/lacunar leukoencephalopathy of unspecified etiology
7. Amyloidosis
8. Demyelinating diseases (CSF examination)
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trigger the search for medical assistance, and they may be
crucial in guiding treatment. Organ involvement should be
monitored in male and female Fabry patients, ideally in
specialized healthcare facilities. The following evaluations
are useful in monitoring peripheral and central nervous
system involvement in male and female patients, even in
asymptomatic patients and in patients who are not under-
going treatment:
1. neurological assessment;
2. disability and quality of life evaluation, e.g. with
Rankin scale [28], Euro-Qol [29], and Mainz Severity
Score Index or MSSI [30], together with the traditional
SF-36 quality of scale, which is used in the Fabry
Registry;
3. non contrast-enhanced MRI of the brain with MRI
angiography of intracranial vessels;
4. diagnostic ultrasonography of neck vessels;
5. examination and evaluation for cardiovascular risk—
i.e., combination of common acquired or genetic risk
factors.
Clinical course will determine frequency of tests and
clinical evaluation. Annual evaluations are also warranted
for asymptomatic individuals, especially in women, for
early detection of central nervous system involvement. In
patients undergoing ERT, recommended examinations
should be performed according to clinical opportunity, or at
least once a year in the first 2 years of treatment.
Other examinations, which are useful for the neurolo-
gist, are
1. NCS (usefulness is limited, but it can reveal the
coexistence of other neuropathic conditions such as
kidney failure or dialysis-associated polyneuropathy);
2. skin biopsy for studying intraepidermic innervation
(skin biopsy may be also warranted to look for
indications of small fiber neuropathy).
Enzyme replacement therapy
Specific pharmacologic therapy for Fabry disease with ERT
is endorsed by health regulatory agencies. Two authorized
drugs are available in Europe for ERT in Fabry disease.
Characteristics and efficacy data of the two drugs are
summarized in two recent articles [31, 32]; the management
of multiorgan involvement is described in Eng et al. [33].
Both are administered intravenously, with one infusion
every 14 days. Agalsidase beta (Fabrazyme) is approved
for maintenance regimens of 1 mg/kg every 14 days. A
dose of 0.3 mg/kg (after a 24-month 1 mg/kg treatment and
depending on assessment of clinical course) may maintain
GL-3 clearance in some patients with Fabry disease, but
other patients seem to require a dose higher than 0.3 mg/kg
to prevent recurrence of GL-3 accumulation in cells. The
long-term clinical effects of transitioning to the lower dose
were not evaluated. Nevertheless, the results clearly show
variability in responsiveness to the lower dose of agalsidase
beta and suggest that dosing strategies that deviate from the
recommended therapeutic regimen of 1.0 mg/kg every
2 weeks should be systematically monitored [34]. Agalsi-
dase alpha (Replagal) is approved for maintenance regi-
mens of 0.2 mg/kg every 14 days.
Evidence of efficacy is available for each product [34–
39] and dosage. However, disease progression is also
reported with both drugs, at least in the first years of ERT
in patients in late clinical stages and with organ damage
[7, 26]. Both synthetic enzymes do not cross the BBB.
Treatments can, therefore, only act on the endothelial cells
of the cerebral arterial circulation, at least when the BBB is
intact (in aggressive or MS-like and aseptic meningitis-like
forms of Fabry disease with lacunar infarcts, BBB may be
seriously altered). At present, long longitudinal studies
with adequate number of enrolled patients are not yet
available to support evidence of efficacy of ERT in pre-
venting new cerebrovascular events.
Young or adult Fabry disease patients with a genetic
mutation leading to a lack or marked reduction in leukocyte
alpha-galactosidase A are eligible to undergo ERT even
with simple evidence of angiokeratoma and/or painful
neuropathy and before the onset of signs of vital organ
damage (male patients with the classic form of the disease).
Prognosis for this group of patients is actually rather pre-
dictable, with high likelihood of developing terminal renal
failure around age of 40 years. Fabry male patients with
atypical clinical features—residual leukocyte alpha-galac-
tosidase A activity, prevalent cardiovascular involvement,
lengthy clinical course and lack of evidence of angiokera-
toma, painful polyneuropathy—could be treated when rel-
evant signs and symptoms are present. This more cautious
conduct in initiating treatment is justified by lack of definite
knowledge about the long-term prognosis of these patients.
ERT is indicated in women as well, but guidelines pub-
lished in other countries (Great Britain, Australia, Canada),
and also guidelines by an expert panel [33] restrict its use to
women with clinical signs or symptoms, always because of
difficulties in predicting the outcome in the individual
patient. In the literature, there are several evidences of
symptoms improvement, as well as reports of improvement
of some indicators of painful neuropathy and of hypo/
anhydrosis [40–42]. These latter signs are also supported by
clinical evidence, even if there is no evidence of intraepi-
dermic nerves regeneration [43]. As a matter of fact, usually
neuropathic pain and hypo/anhydrosis do respond to ERT,
either in men either in women. In male patients, such
symptoms are frequent, almost always in combination with
302 Neurol Sci (2010) 31:299–306
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overt multiorgan clinical manifestations, while in women
neuropathic pain can either be an isolated symptom or it can
be one of the major symptoms. The follow-up is always
important for assessing the real impact of ERT on neuro-
pathic pain. Evidence of a favorable impact of ERT on
central nervous system signs and symptoms has not yet been
established. All favorable data, e.g., functional modifica-
tions of cerebral arterial circulation, assessed mainly with
transcranial Doppler, are still under discussion and inter-
pretation [23, 24]. Furthermore, documented structural
alterations of cerebral parenchyma and/or cerebral vessels
must be considered as non-early complications. Decision to
start ERT, especially in men, is, therefore, rarely taken
based only on the involvement of the nervous system,
except for the following circumstances:
1. rare, very aggressive forms in young men with
predominant CNS symptoms and not much evidence
of classic signs (neuropathy, angiokeratoma);
2. women and men with atypical presentation, with
prevalent clinical manifestation and/or neuroradiological
specific involvement of central nervous system (TIA or
stroke; subclinical MRI abnormalities, i.e. white matter
changes), even when onset is late (e.g., 40–50 years).
ERT is authorized in Europe for all confirmed Fabry
patients, regardless of organ involvement and clinical
severity. For patients with prevalent central nervous system
involvement, ERT should be prescribed by specialized phy-
sicians taking into consideration the following conditions:
1. without a confirmatory kidney biopsy, the medical
team should ascertain that Fabry disease has a
pathogenetic role. Finding of central nervous system
MRI preclinical abnormalities, when correctly
assessed by an expert team, may indicate a precocious
stage of the disease, which could benefit of an early
treatment, even though we do not have yet clinical
studies which demonstrate such a result;
2. the patient must be informed of our limited current
knowledge on this specific topic;
3. careful monitoring of the clinical course of disease and
outcome of treatment are mandatory;
4. it must be kept in mind that cerebrovascular manifes-
tations of Fabry disease often have a multifactorial
pathogenesis—i.e., genetic and acquired risk factors
for cerebrovascular disease and multiorgan involve-
ment (cardiovascular and renal damage), including
alterations of blood pressure regulation with arterial
hypo-hypertension, both directly or indirectly linked to
Fabry disease. Therefore, support therapy, i.e. anti-
platelet or anticoagulant treatment and care of poten-
tially associated cerebrovascular risk factors, should
always be started together with the ERT.
Home-based ERT
Enzyme replacement therapy is a lifelong therapy. As
home-based therapy, it could be beneficial for quality of
life and optimization of healthcare resources. Some studies
reported that home-based therapy is feasible and advanta-
geous for both patients and the healthcare systems, pro-
vided that the patient is stable; his dwelling is suitable,
community-based services are adequate, and intervention
protocols for treatment of potential reaction associated with
the infusion are in place [44–46].
Symptomatic and preventive therapy
Kidney transplants have changed life perspectives of Fabry
patients. Other important preventive and support treat-
ments, include antiplatelet drugs, anticoagulants, antiar-
rhythmics, ICDs, pacemaker, ACE inhibitors for
proteinuria, and dialysis. Moreover, prevention measures
addressing multifactorial vascular risk also have a key role
in Fabry patients—e.g., treatments for hypertension.
Gabapentin and carbamazepine may be effective symp-
tomatic treatments for neuropathic pain [47, 48]; such
treatments are often carried out in the setting of clinical
teams including many specialists. Satisfactory results,
albeit limited in time, have been recently reported in
aggressive CNS involvement (MS-like forms or aseptic
meningitis with lacunar infarctions) with bolus high-dose
cortisone [49]; the authors also observed temporary bene-
ficial effects of corticosteroid treatment in these cases.
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Appendix: neurologic group consensus: early diagnosis
of Fabry disease
Recommendation 1
Suspected Fabry disease should be confirmed as follows
Leukocyte alpha-galactosidase A activity assay in men (in the
classic form of disease, enzyme activity is always very low or
absent)
In women, and more rarely in men with residual enzyme activity,
molecular analysis of GLA gene must be performed
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Recommendation 2
Recognize the variable nervous system involvement in Fabry
disease
Painful neuropathy (small fiber neuropathy)
Cerebrovascular disorders (small and large vessels and/or
cardiovascular disorders with cerebral embolism)
Aggressive forms with multifocal, relapsing central symptoms,
and progressive disability (multiple sclerosis-like and/or aseptic
meningitis)
Recommendation 3
Recognize painful neuropathy of Fabry disease for early diagnosis
Painful neuropathy
Early onset (usually childhood), especially in men
Association between neuropathic pain and retained tendon
reflexes and normal NCS
Association with intolerance to extreme temperatures and hypo/
anhydrosis
Small fiber neuropathy (skin biopsy)
Recommendation 4
Fabry disease is often unrecognized as a cause of TIA/stroke
[TIA/stroke
In young men, and in women or in men with atypical forms, aged
40–50 years
Cerebral embolism in patients with atrial fibrillation, even at age
[50 years
Association with intolerance to extreme temperatures and hypo/
anhydrosis
Association with one or more of the following clinical features as
angiokeratoma, cornea verticillata, proteinuria, and painful
neuropathy in women and men
Should TIA/stroke or brain MRI signs confirm small vessel disease in
a patient aged 55 years or younger, consider Fabry disease. Brain
MRI (Flair sequence) detects small cerebral vessels alteration with
high sensitivity, but it lacks specificity
Documenting multiorgan damage
Recommendation 5
Validate diagnosis of organ damage
Early documentation of organ damage in patients with confirmed
diagnosis is currently considered an important feature to guide
treatment in clinical practice
Attribute a score to the extent of damage in the peripheral nervous
system
Neurologists will document peripheral nervous system
involvement
Appendix continued
Scoring systems are used to assess neuropathic pain and monitor
changes (visual analog scale or VAS, Brief Pain Inventory or BPI
[50], McGill Pain Questionnaire) [51]
Skin biopsy with study of intraepidermic innervation should
currently be reserved to specific cases
NCS has a role in differential diagnosis with large fiber
neuropathy, which may also be seen in Fabry disease (e.g., with
progression of kidney failure)
Recommendation 6
Useful tests to monitor cerebrovascular disorders in patients with
Fabry disease
Recommended investigations for early evaluation and monitoring
of CNS damage
Anamnesis, genetic family tree, and neurological examination
Assessment of general health status (Rankin, EuroQoL, SF-36,
WHOQoL-100)
Brain MRI (including T1 sequence for identification of the
pulvinar sign, and intracranial MRI angiography)
Diagnostic ultrasonography of epiaortic vessels
Cardiologic evaluation, EKG and echocardiography
Assessment of modifiable cardiovascular risk factors (e.g.,
homocysteinemia, folate serum levels, etc.)
Biopsy for vasculitis
Clinical evaluation suggests timing of examinations (at least
yearly)
Monitoring of ERT patients on ERT should be performed with the
same tests, which will be repeated at least once a year for the first
2 years of treatment or according to clinical considerations
Therapy
Recommendation 7
Health Regulatory Agencies recommend ERT in confirmed Fabry
disease
Any decision on treatment should be made by considering the full
clinical presentation
Due to reduction in life expectancy, affected males should start
ERT even during adolescence if angiokeratoma and/or painful
neuropathy are reported
Male patients with atypical clinical forms (with residual
leukocyte alpha-galactosidase A, absence of angiokeratoma and
painful polyneuropathy, slower clinical progression) should be
treated at onset of organ involvement, even without related
symptoms
Not all affected women should be treated, but only those with
involvement of vital organs or significant neuropathic pain
ERT is prescribed in clinical settings specialized in the diagnosis
and care of Fabry disease
304 Neurol Sci (2010) 31:299–306
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Recommendation 8
Enzyme replacement therapy is effective in the treatment of painful
neuropathy
Assess what symptoms are due to Fabry disease
Assess relevance of symptoms for the patient’s quality of life—
mainly in women with only one symptom or sign
Make sure the patient is adequately informed on treatment and
compliance is maintained
Carry out correctly the patient’s follow-up
Identify a symptomatic drug for the treatment of the neuropathic
pain (e.g., gabapentin)
Recommendation 9
Efficacy of enzyme replacement therapy on central nervous system
involvement is currently not established
Further investigations are required
If ERT is started in symptomatic patients, progression of disease
may still occur
Neurologists should focus on preclinical detection of CNS
involvement
If ERT is prescribed for central nervous system involvement, as
may be the case for women, a decision, carried out by a team of
experts, for any single patient is recommended with the following
goals
Assessing that symptoms to Fabry disease are correctly identified
Designing a multitarget treatment (for prevention of cardio- and
cerebrovascular risks)
Evaluating awareness and compliance of patient with the
treatment program
Carrying out correctly the patient’s follow-up
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